-
公开(公告)号：US20170231981A1
公开(公告)日：2017-08-17
申请号：US15435170
申请日：2017-02-16
发明人： Tarek A. ZEIDAN , David MANSER , Kristopher Perkin , Philip CRESSWELL , Magali HICKEY , Brian STEINBERG
IPC分类号： A61K31/496 , A61K9/00 , A61K9/14
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/10 , A61K9/14 , A61K9/145 , A61K9/146 , A61K47/10 , A61K47/26 , A61K2300/00
摘要： Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.
-
公开(公告)号：US09517235B2
公开(公告)日：2016-12-13
申请号：US14813260
申请日：2015-07-30
发明人： Daniel Deaver , Mark Todtenkopf
IPC分类号： A61K31/554 , C07D221/28 , C07D405/06 , A61K31/485 , A61K31/439 , A61K31/496 , A61K31/519 , A61K31/5513
CPC分类号： A61K31/485 , A61K9/20 , A61K31/439 , A61K31/496 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K31/554 , C07D221/28 , C07D405/06
摘要： The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
-
公开(公告)号：US09452131B2
公开(公告)日：2016-09-27
申请号：US14663042
申请日：2015-03-19
IPC分类号： A61K31/497 , A61K9/00 , A61K31/496 , A61K47/26
CPC分类号： A61K31/496 , A61K9/0019 , A61K31/00 , A61K47/26
摘要： The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
摘要翻译： 本发明涉及包含式（I）化合物的药物组合物，其可用于使用快速注射速率肌内递送抗精神病药物。
-
公开(公告)号：US20160228555A1
公开(公告)日：2016-08-11
申请号：US15130331
申请日：2016-04-15
发明人： Niels P. Ryde , Peter Snyder , Wei Liu , David M. Slifer
CPC分类号： A61K9/1623 , A61K9/0019 , A61K9/10 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1688 , A61K31/5415 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/28 , A61K47/32
摘要： This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
-
公开(公告)号：US09365580B2
公开(公告)日：2016-06-14
申请号：US14945607
申请日：2015-11-19
发明人： Harry G. Brittain , David A. Dickason , Joyce M. Hotz , Shawn L. Lyons , J. Michael Ramstack , Steven G. Wright
IPC分类号： A61K31/485 , C07D489/08 , C07C19/03
CPC分类号： A61K31/485 , C07B2200/13 , C07C19/03 , C07D489/06 , C07D489/08
摘要： This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
摘要翻译： 本发明涉及纳曲酮的新型多晶型物的发现，包括溶剂化物，水合物，无水和其它结晶形式及其组合。纳他酮的这些新型形式在掺入其中的药物制剂中赋予其优势，包括持续释放或长效制剂。
-
公开(公告)号：US09351976B2
公开(公告)日：2016-05-31
申请号：US14714621
申请日：2015-05-18
IPC分类号： A61K31/551 , A61K9/00 , A61K47/26 , A61K31/5513 , A61K31/4965 , A61K31/497 , A61K9/10 , A61K31/496
CPC分类号： A61K31/496 , A61K9/0019 , A61K9/10 , A61K31/4965 , A61K31/497 , A61K31/551 , A61K31/5513 , A61K47/26
摘要： The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
-
公开(公告)号：US09101549B2
公开(公告)日：2015-08-11
申请号：US14536539
申请日：2014-11-07
发明人： Douglas Hovey , John Pruitt , Tuula Ryde
IPC分类号： A61K9/51 , A61K9/14 , A61K47/42 , A61K31/573 , A61K47/26 , A61K47/34 , A61K47/32 , A61K47/38 , A61K47/20 , A61K9/08 , A61K9/00 , A61K9/10 , A61K31/57 , A61K45/06
CPC分类号： A61K9/14 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K9/145 , A61K9/146 , A61K9/5123 , A61K9/5138 , A61K9/5161 , A61K9/5169 , A61K31/57 , A61K31/573 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/38 , A61K47/42 , A61K2300/00
摘要： The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
-
公开(公告)号：US09040088B2
公开(公告)日：2015-05-26
申请号：US14536517
申请日：2014-11-07
发明人： Douglas Hovey , John Pruitt , Tuula Ryde
IPC分类号： A61K9/14 , A61K9/00 , A61K9/10 , A61K31/57 , A61K45/06 , A61K47/20 , A61K47/32 , A61K47/38 , A61K9/08 , A61K31/573 , A61K47/26 , A61K47/34 , A61K47/42
CPC分类号： A61K9/14 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K9/145 , A61K9/146 , A61K9/5123 , A61K9/5138 , A61K9/5161 , A61K9/5169 , A61K31/57 , A61K31/573 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/38 , A61K47/42 , A61K2300/00
摘要： The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
-
公开(公告)号：US09012511B2
公开(公告)日：2015-04-21
申请号：US13110647
申请日：2011-05-18
申请人： Deborah Neville , Scott Jenkins , David Manser
发明人： Deborah Neville , Scott Jenkins , David Manser
IPC分类号： A01N33/02 , A01N33/24 , A61K31/13 , A61K31/135 , A61K9/14 , A61K9/16 , A61K9/50 , A61K31/137 , A61K9/10 , A61K9/51
CPC分类号： A61K31/137 , A61K9/10 , A61K9/1605 , A61K9/5138 , A61K9/5146 , A61K9/5161 , A61K9/5192
摘要： Described are compositions of stable nanoparticulate cinacalcet or a salt thereof, and methods of making and using them. The compositions exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions.
摘要翻译： 描述了稳定的纳米颗粒西那卡塞或其盐的组合物，以及制备和使用它们的方法。 与空腹相比，组合物表现出改善的溶解速率，改善的生物利用度，以及在进食时口服时减少的吸收差异。
-
公开(公告)号：US20150072971A1
公开(公告)日：2015-03-12
申请号：US14286499
申请日：2014-05-23
发明人： Laura Cook Blumberg , Dan Deaver , David Eyerman , Thomas Wynn
IPC分类号： C07D221/28 , C07D221/22 , C07D401/12 , C07D489/09 , C07D211/62 , C07D217/04 , C07D223/04 , C07D405/12 , C07D489/00
CPC分类号： A61K31/485 , C07D211/62 , C07D217/04 , C07D221/22 , C07D221/28 , C07D223/04 , C07D401/12 , C07D405/12 , C07D489/00 , C07D489/09
摘要： The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
摘要翻译： 本申请涉及治疗抑郁症状的方法，包括向有需要的受试者施用有效量的μ阿片受体激动剂或其药学上可接受的盐。 这种激动剂的非限制性实例包括式I，II，III和IV的化合物，以及表A的化合物。
-
-
-
-
-
-
-
-
-
搜索结果
252 条记录 (耗时 0.06 秒)
